Launch of mobile processing laboratories to detect COVID-19

Paris, France and Camberley, UK – 17 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ service with the launch of mobile processing laboratories (MPL) to provide rapid turnaround polymerase chain reaction (PCR) testing on-site. Testing will be performed using mid-nose nasal swabs,

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 15 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 15 March 2021 that, as at 12 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.81% (1,986,434 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-15.03.2021-ENGLISH-No.-2.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 15 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 12 March 2021 that, as at 11 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 3% (2,119,828 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-15.03.2021-ENGLISH.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 12 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 11 March 2021 that, as at 10 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.99% (2,117,183 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-12.03.2021-ENGLISH.pdf

Visit Page

Correction: Research and Development Update

This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8am CET on 24 February 2021. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-correction-ENGLISH.pdf

Visit Page

Research and Development Update

Paris, France and Camberley, UK – 24 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term research and development programmes, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of the Company’s COVID-19

Visit Page

Launch of PCR genotyping assay portfolio to detect COVID-19 variants

Paris, France and Camberley, UK – 2 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig®) to aid the diagnosis of the new variants of SARS-CoV-2. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-Variants-launch-02.02.21-ENGLISH.pdf

Visit Page

Full Year 2020 Trading Update

Paris, France and Camberley, UK – 29 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2020. http://novacyt.com/wp-content/uploads/2021/01/Novacyt-Trading-Update-29.01.2021-ENGLISH.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 26 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 26 January 2021 that, as at 25 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 3.02% (2,132,372 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-26.01.2021-ENGLISH.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 13 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 12 January 2021 that, as at 11 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.95% (2,085,368 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-13.01.2021-ENGLISH.pdf

Visit Page